Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 multi-center, long-term extension study investigating the efficacy and safety of Abrocitinib, with or without topical medications, administered to subjects aged 12 years and older with moderate to severe atopic dermatitis

Next Previous
Trial Profile

A phase 3 multi-center, long-term extension study investigating the efficacy and safety of Abrocitinib, with or without topical medications, administered to subjects aged 12 years and older with moderate to severe atopic dermatitis

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abrocitinib (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Registrational
  • Acronyms JADE EXTEND
  • Sponsors Pfizer

    • Most Recent Events

    • 01 Oct 2023 Results of pooled analysis from JADE MONO-1 (NCT03349060), JADE MONO-2 (NCT03575871) and JADE COMPARE (NCT03720470) and JADE EXTEND assessing patient-reported outcomes with long-term abrocitinib treatment in patients with moderate-to-severe AD published in the Journal of the European Academy of Dermatology and Venereology
    • 01 Oct 2023 Results from three phase 3 studies( JADE MONO1 (NCT03349060), JADE MONO2 (NCT03575871) and JADE COMPARE (NCT03720470)), including the long term extension JADE EXTEND study(Data cut-off: April 22, 2020) evaluating efficacy of abrocitinib and long term safety in patients with moderate to severe AD, published in the Journal of the European Academy of Dermatology and Venereology.
    • 24 Apr 2023 Planned End Date changed from 30 Jun 2025 to 31 Jan 2026.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top